Emily B. Shacter, Ph.D.
CBER Research Projects
CBER Research - Office of Therapeutics Research and Review
Division of Therapeutic Proteins
Emily B. Shacter, Ph.D.
Chronic Inflammation and Cancer
We are investigating how inflammatory oxidants such as hydrogen peroxide and hypochlorous acid kill tumor cells and how they may affect tumor cell recognition and elimination by the immune system. Solid tumors are often infiltrated by inflammatory phagocytes which can generate reactive oxygen species within the tumor tissue. Our studies focus on determining how these oxidants kill tumor cells so that we may better understand mechanisms of cell death. In addition, we are studying how these oxidants may influence the ability of chemotherapy drugs to kill cancer cells. The overall goal of the research is to find ways to improve cancer treatment by using our knowledge of basic biochemical and immunological mechanisms to develop novel therapeutic approaches for eliminating tumors.
Current laboratory members:
Howard A. Anderson, Ph.D., Staff Fellow
Baolin, Zhang, Ph.D., Visiting Associate
Shoshana Bar-Noy, Ph.D., Visiting Associate
Yaqin Zhang, M.D., ORISE Fellow/technician
Eileen Dwyer Hoke, M.D., Guest Researcher (part time)
CBER Research Projects:
Recent Representative Publications:
Englert, R.P. and Shacter, E. Distinct modes of cell death induced by different reactive oxygen species: Amino acyl chloramines mediate hypochlorous acid-induced apoptosis. J Biol Chem 2002 Jun 7;277(23):20518-26.
Anderson HA, Englert R, Gursel I, Shacter E. Oxidative stress inhibits the phagocytosis of apoptotic cells that have externalized phosphatidylserine. Cell Death Differ 2002 Jun;9(6):616-25.
Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Huntingt). 2002 Feb;16(2):217-26, 229; discussion 230-2.
Senturker S, Tschirret-Guth R, Morrow J, Levine R, Shacter E. Induction of apoptosis by chemotherapeutic drugs without generation of reactive oxygen species. Arch Biochem Biophys 2002 Jan 15;397(2):262-72.
Shacter E. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev 2000 Aug-Nov;32(3-4):307-26.
Recent Invited Oral Presentations:
Shacter, E. "Technology Transfer: Regulatory Perspectives," Parenteral Drug Association (PDA) Italy Chapter meeting, April 2002, Milan, Italy.
Shacter, E. "Oxidants and apoptosis" seminar, NIH Apoptosis Interest group, February 2002, Bethesda, MD.
Shacter, E. "Reprocessing: FDA Regulatory Perspectives," Parenteral Drug Association (PDA) International Congress, February 11-13, 2002, Basel, Switzerland.
Shacter, E. "Reprocessing of Biological Products Workshop," PDA International Conference on Process Validation for Manufacturing of Biologics and Biotechnology Products, September 2001, Berlin, Germany.
Shacter, E. "Effects of oxidants on death and phagocytosis of tumor cells," NYU School of Medicine, May 2001, New York, NY.